Back to Search Start Over

Let there be light: gene and cell therapy for blindness

Authors :
José-Alain Sahel
Deniz Dalkara
Olivier Goureau
Katia Marazova
Marazova, Katia
Sorbonne Universités à Paris pour l'Enseignement et la Recherche - - SUPER2011 - ANR-11-IDEX-0004 - IDEX - VALID
Institut de la Vision
Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (CHNO)
Département Ophtalomologie Pathologies Vitréo-Rétiniennes
Fondation Ophtalmologique Adolphe de Rothschild
This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), Pierre et Marie Curie University (UPMC), the Centre National de la Recherche Scientifique (CNRS), Foundation Fighting Blindness (FFB) [CD-CL-0808-0466-CHNO]
ANR-11-IDEX-0004,SUPER,Sorbonne Universités à Paris pour l'Enseignement et la Recherche(2011)
Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)
Fondation Ophtalmologique Adolphe de Rothschild [Paris]
Source :
Human Gene Therapy, Human Gene Therapy, 2016, 27 (2), pp.134-47, Human Gene Therapy, Mary Ann Liebert, 2016, 27 (2), pp.134-47
Publication Year :
2016
Publisher :
HAL CCSD, 2016.

Abstract

International audience; Retinal degenerative diseases are a leading cause of irreversible blindness. Retinal cell death is the main cause of vision loss in genetic disorders such as retinitis pigmentosa, Stargardt disease and Leber congenital amaurosis, as well as in complex age-related diseases such as age-related macular degeneration (AMD). For these blinding conditions, gene and cell therapy approaches offer therapeutic intervention at various disease stages. The present review outlines recent advances in therapies for retinal degenerative disease, focusing on the progress and challenges in the development and clinical translation of gene and cell therapies. A significant body of preclinical evidence and initial clinical results pave the way for further development of these cutting edge treatments for patients with retinal degenerative disorders.

Details

Language :
English
ISSN :
10430342
Database :
OpenAIRE
Journal :
Human Gene Therapy, Human Gene Therapy, 2016, 27 (2), pp.134-47, Human Gene Therapy, Mary Ann Liebert, 2016, 27 (2), pp.134-47
Accession number :
edsair.doi.dedup.....93c049f2c7949c6a012548f3ecd4518e